… myeloid leukemia with t (8; 16)(p11; p13), a distinct clinical and biological entity: a collaborative study by the International-Berlin-Frankfurt-Münster AML-study group

EA Coenen, CM Zwaan, D Reinhardt… - Blood, The Journal …, 2013 - ashpublications.org
… AML cases clustered close to, but distinct from, MLL-rearranged AML. … , pediatric t(8;16)(p11;p13)
AML is a rare entity defined by a unique gene expression signature and distinct clinical

[HTML][HTML] … t (8; 16)(p11; p13): A Distinct Clinical and Biological Entity. Results of a Collaborative Study by the International Berlin-Frankfurt-Münster AML Study Group.

EA Coenen, CM Zwaan, CJ Harrison, OA Haas… - Blood, 2012 - Elsevier
… This study shows the distinct nature of t(8;16)(p11;p13) pediatric AML with remarkable clinical
features such as high percentage of leukemia … The 5-year OS of this pediatric cohort was …

Prognostic impact of t (16; 21)(p11; q22) and t (16; 21)(q24; q22) in pediatric AML: a retrospective study by the I-BFM Study Group

S Noort, M Zimmermann, D Reinhardt… - Blood, The Journal …, 2018 - ashpublications.org
… the international Berlin-Frankfurt-Münster (I-BFM) AML study … aim of this study was to
describe the biological and clinical … KMT2A rearrangements, t(16;21)(q22;q22) and inv(16)(p13;q22)…

A large co‐operative biological and clinical study to better understand and improve treatment of the rare t (8; 16)(p11; p13) acute myeloid leukaemia.

MW Becker, E Angelucci - British Journal of Haematology, 2021 - search.ebscohost.com
Pediatric acute myeloid leukemia with t(8;16)(p11;p13), a distinct clinical and biological entity:
a collaborative study by the InternationalBerlin-Frankfurt-Munster AML-study group. Blood. …

[PDF][PDF] Pediatric Acute Myeloid Leukemia with t (8; 16)(p11; p13): a distinct clinical and biological entity.

EA Coenen, CM Zwaan, D Reinhardt, CJ Harrison… - 2013 - Citeseer
study that was conducted within the framework of the International Berlin-Frankfurt-Münster
(I-BFM) AML studycollaborative study describes the rare entity of pediatric t(8;16)(…

[HTML][HTML] Acute myeloid leukemia with rare recurring translocations—an overview of the entities included in the international consensus classification

SD Rørvik, S Torkildsen, Ø Bruserud, THA Tvedt - Annals of Hematology, 2024 - Springer
different systems exist for subclassification of acute myeloid … 2 Studies on clinical
characteristics and outcome in pediatric … A total of 159 cases of AML carrying the t(8;16)(p11;p13) …

Acute myeloid leukemia and translocation (8; 16)(p11; p13), the first Moroccan case of a distinct clinical-biological entity

A Bakkali, M Lemchaheb, N Had, H Dehbi… - … Pan African Medical …, 2015 - europepmc.org
… La t(8;16)(p11;p13) est rare au cours de cette pathologie. Nous décrivons le cas d'une
patiente de 22 ans, admise pour un syndrome d'insuffisance médullaire complet associé à une …

[HTML][HTML] Collaborative efforts driving progress in pediatric acute myeloid leukemia

CM Zwaan, EA Kolb, D Reinhardt… - Journal of clinical …, 2015 - ncbi.nlm.nih.gov
Collaboration has evolved to encompass different … The t(8;16)(p11;p13) translocation may
have an age-dependent … The BFM-AML Study Group currently employs a high dose of DNX (…

Acute myeloid leukemia with t(8;16)(p11.2;p13.3)/KAT6A-CREBBP in adults

W Xie, S Hu, J Xu, Z Chen, LJ Medeiros, G Tang - Annals of hematology, 2019 - Springer
… adult and pediatric patients [1, 3,4,5,6,7,8,9]. AML with … greatly in different reports and in
different age groups. In this … The clinical features are summarized in Table 1. A total of 15 …

[HTML][HTML] Acute myeloid leukemia in an infant with t (8; 19)(p11. 2; q13) translocation: case report and a review of the literature

AC Eason, ST Bunting, JF Peterson, D Saxe… - Case reports in …, 2019 - hindawi.com
International Berlin-Frankfurt-Munster (I-BFM) AML study group reviewed 62 patients with
t(8; 16)(p11.2;p13) and compared them with a pediatric AML reference cohort [3]. Nearly all …